BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an increasingly utilized strategy for patients with peritoneal surface malignancies (PSM). METHODS: The US HIPEC Collaborative was retrospectively reviewed to compare the indications and perioperative outcomes of patients who underwent CRS ± HIPEC between 2000 and 2012 (P1) versus 2013-2017 (P2). RESULTS: Among 2,364 patients, 39% were from P1 and 61% from P2. The most common primary site was appendiceal (64%) while the median PCI was 13 and most patients had CCR 0 (60%) or 1 (25%). Over time, median estimated blood loss, need for transfusion, and length of hospital stay decreased. While the incidence of any (55% vs. 57%; p = 0.426) and Clavien III/IV complications did not change over time, there was a decrease in 90-day mortality (5% vs. 3%; p = 0.045). CONCLUSION: CRS-HIPEC is increasingly performed for PSM at high-volume centers. Despite improvements in some perioperative outcomes and a reduction in postoperative mortality, morbidity rates remain high.
BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an increasingly utilized strategy for patients with peritoneal surface malignancies (PSM). METHODS: The US HIPEC Collaborative was retrospectively reviewed to compare the indications and perioperative outcomes of patients who underwent CRS ± HIPEC between 2000 and 2012 (P1) versus 2013-2017 (P2). RESULTS: Among 2,364 patients, 39% were from P1 and 61% from P2. The most common primary site was appendiceal (64%) while the median PCI was 13 and most patients had CCR 0 (60%) or 1 (25%). Over time, median estimated blood loss, need for transfusion, and length of hospital stay decreased. While the incidence of any (55% vs. 57%; p = 0.426) and Clavien III/IV complications did not change over time, there was a decrease in 90-day mortality (5% vs. 3%; p = 0.045). CONCLUSION: CRS-HIPEC is increasingly performed for PSM at high-volume centers. Despite improvements in some perioperative outcomes and a reduction in postoperative mortality, morbidity rates remain high.
Authors: Travis E Grotz; Jennifer A Yonkus; Cornelius A Thiels; Susanne G Warner; Robert R McWilliams; Amit Mahipal; Tanios S Bekaii-Saab; Sean P Cleary; Michael L Kendrick; Mark J Truty Journal: Ann Surg Oncol Date: 2022-08-16 Impact factor: 4.339
Authors: Patrick B Schwartz; Christopher C Stahl; Roberto J Vidri; Glen E Leverson; Yana Puckett; Syed N Zafar; Patrick Varley; Sean M Ronnekleiv-Kelly; Ahmed Al-Niaimi; Sharon M Weber; Daniel E Abbott Journal: Ann Surg Oncol Date: 2022-06-07 Impact factor: 4.339
Authors: Kevin M Turner; Mackenzie C Morris; Aaron M Delman; Dennis Hanseman; Fabian M Johnston; Jonathan Greer; Kara Vande Walle; Daniel E Abbott; Mustafa Raoof; Travis E Grotz; Keith Fournier; Sean Dineen; Jula Veerapong; Ugwuji Maduekwe; Anai Kothari; Charles A Staley; Shishir K Maithel; Laura A Lambert; Alex C Kim; Jordan M Cloyd; Gregory C Wilson; Jeffrey J Sussman; Syed A Ahmad; Sameer H Patel Journal: J Gastrointest Surg Date: 2022-10-18 Impact factor: 3.267
Authors: Huiyu Deng; Zahra Eftekhari; Cameron Carlin; Jula Veerapong; Keith F Fournier; Fabian M Johnston; Sean P Dineen; Benjamin D Powers; Ryan Hendrix; Laura A Lambert; Daniel E Abbott; Kara Vande Walle; Travis E Grotz; Sameer H Patel; Callisia N Clarke; Charles A Staley; Sherif Abdel-Misih; Jordan M Cloyd; Byrne Lee; Yuman Fong; Mustafa Raoof Journal: JAMA Netw Open Date: 2022-05-02
Authors: Patrick B Schwartz; Christopher C Stahl; Kara A Vande Walle; Courtney J Pokrzywa; Linda M Cherney Stafford; Taylor Aiken; James Barrett; Alexandra W Acher; Glen Leverson; Sean Ronnekleiv-Kelly; Sharon M Weber; Daniel E Abbott Journal: Ann Surg Oncol Date: 2020-05-15 Impact factor: 5.344
Authors: Anna Coghill; Julian Sanchez; Sweta Sinha; Jennifer B Permuth; Danielle Laskowitz; Benjamin D Powers; Sean P Dineen Journal: Cancer Rep (Hoboken) Date: 2022-07-22